Altered cytokine and acute phase response protein levels in the blood of children with Downs syndrome: relationship with dementia of Alzheimer's type
- PMID: 15698521
- DOI: 10.1177/039463200501800117
Altered cytokine and acute phase response protein levels in the blood of children with Downs syndrome: relationship with dementia of Alzheimer's type
Abstract
Downs syndrome (DS) subjects are at high risk of developing Alzheimer's disease (AD). Patients with AD often show altered levels of some immune molecules in their peripheral blood which correlate with cognitive impairment. However, whether the altered peripheral immune phenotype is a late and secondary phenomenon associated with dementia or an early impairment linked to mechanisms controlling neurodegeneration of the central nervous system (CNS) is still an unanswered question. Here we studied immune molecules in the blood of non demented children with DS to investigate whether altered peripheral immune phenotype could be present in these subjects without dementia, many years before the presentation of clinical signs of cognitive deterioration. Plasma levels of interleukin-6 (IL-6) and soluble IL-6 receptor (sIL-6R) were significantly higher in DS than in control children. Plasma levels of soluble intercellular adhesion molecule-3 (sICAM-3), soluble vascular cell adhesion molecule-1 (sVCAM-1) and C reactive protein (CRP) were also increased in DS. The increase of IL-6 and CRP from DS children was similar to that found in elderly patients with clinical AD. Peripheral altered immune phenotype in healthy young subjects with DS might be an early sign of CNS alterations leading many years later to cognitive deterioration and dementia.
Similar articles
-
[Relation of serum levels of the soluble cytoadhesion molecules sVCAM-1 and sICAM-1 to selected factors in the cytokine network in multiple myeloma].Cas Lek Cesk. 2000 Jul 5;139(13):401-6. Cas Lek Cesk. 2000. PMID: 10971970 Slovak.
-
Altered vessel signalling molecules in subjects with Downs syndrome.Int J Immunopathol Pharmacol. 2006 Jan-Mar;19(1):181-5. Int J Immunopathol Pharmacol. 2006. PMID: 16569356
-
[Soluble adhesive molecules and cytokines in patients with myasthenia gravis treated with plasmapheresis].Cas Lek Cesk. 1998 Nov 2;137(21):654-9. Cas Lek Cesk. 1998. PMID: 9929930 Czech.
-
Serum MHPG strongly predicts conversion to Alzheimer's disease in behaviorally characterized subjects with Down syndrome.J Alzheimers Dis. 2015;43(3):871-91. doi: 10.3233/JAD-140783. J Alzheimers Dis. 2015. PMID: 25125467
-
Down syndrome, Alzheimer's disease and seizures.Brain Dev. 2005 Jun;27(4):246-52. doi: 10.1016/j.braindev.2004.07.008. Brain Dev. 2005. PMID: 15862185 Review.
Cited by
-
Lung and Heart Biology of the Dp16 Mouse Model of down Syndrome: Implications for Studying Cardiopulmonary Disease.Genes (Basel). 2023 Sep 19;14(9):1819. doi: 10.3390/genes14091819. Genes (Basel). 2023. PMID: 37761959 Free PMC article.
-
Nerve Growth Factor Compromise in Down Syndrome.Front Aging Neurosci. 2021 Aug 9;13:719507. doi: 10.3389/fnagi.2021.719507. eCollection 2021. Front Aging Neurosci. 2021. PMID: 34434101 Free PMC article. Review.
-
Down syndrome and type I interferon: not so simple.Curr Opin Immunol. 2021 Oct;72:196-205. doi: 10.1016/j.coi.2021.06.006. Epub 2021 Jun 23. Curr Opin Immunol. 2021. PMID: 34174697 Free PMC article. Review.
-
Blood-based biomarkers of Alzheimer's disease: challenging but feasible.Biomark Med. 2010 Feb;4(1):65-79. doi: 10.2217/bmm.09.84. Biomark Med. 2010. PMID: 20387303 Free PMC article. Review.
-
The Effects of Exercise on IL-6 Levels and Cognitive Performance in Patients with Schizophrenia.Diseases. 2019 Jan 22;7(1):11. doi: 10.3390/diseases7010011. Diseases. 2019. PMID: 30678202 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous